Partner News | Published: Monday, August 4, 2025
MedAxiom, the cardiovascular community’s premier source for organizational performance solutions, is excited to announce an industry partnership with Alnylam Pharmaceuticals, a global leader in RNA interference (RNAi) therapeutics and the developer of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases, including cardiovascular conditions.
MedAxiom is transforming cardiovascular care by combining the knowledge and power of hundreds of cardiovascular organization members, thousands of administrators, clinicians and revenue cycle experts, and dozens of industry partners. “We are thrilled to welcome Alnylam to the MedAxiom community. With a proven track record of bringing innovative therapies to patients, a collaboration with Alnylam allows for the opportunity to significantly impact care for patients living with ATTR amyloidosis,” said Joe Sasson, PhD, MedAxiom’s executive vice president of Ventures and chief commercial officer. “Alnylam's commitment to advancing innovation for patients living with cardiovascular diseases aligns perfectly with MedAxiom's mission to transform cardiovascular care. We look forward to collaborating with Alnylam to educate and support the cardiovascular community in 2025 and beyond.”
Alnylam has pioneered the translation of Nobel Prize-winning RNAi science into a new class of medicines, offering hope for patients with rare diseases and unmet medical needs. The FDA recently approved an expanded indication for AMVUTTRA® (vutrisiran) to include the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. AMVUTTRA is now the first and only FDA-approved therapy for both ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
“Their unique expertise focused on advancing care delivery and operational excellence in cardiovascular care, combined with their membership of 550+ cardiovascular organizations, along with their relationship with the American College of Cardiology, makes MedAxiom a natural partner for Alnylam,” said Sheri Trutwin, Alnylam’s Vice President of Strategic Accounts. “Partnering with MedAxiom reflects our shared commitment to collaborating with cardiology to improve the care delivery journey for those living with ATTR-CM.”
By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.
